Acadia Pharmaceuticals' rare disease drug fails main goal in late-stage trial
24/09/2025 12:03
Sept 24 (Reuters) - Acadia Pharmaceuticals ACAD.O said on Wednesday that its experimental drug to treat a rare metabolic condition failed to meet the main goal in a late-stage study. (Reporting by Sneha S K; Editing by Sahal Muhammed) ((Sneha.SK@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP